Access cutting-edge ovarian cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access ovarian cancer specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related ovarian cancer treatment provided free
This is an open-label, phase 1/2, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.
Sponsor: TILT Biotherapeutics Ltd.
Check if you qualify for this ovarian cancer clinical trial in New York, NY
If you're searching for ovarian cancer treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ovarian cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.